BIIB Biogen Inc.

Biogen Announces Webcast of Virtual Annual Meeting of Stockholders

Biogen Inc. (NASDAQ: BIIB) announced today that the webcast of the Company's 2017 Annual Meeting of Stockholders will be held on Wednesday, June 7, 2017 at 9:00 a.m. Eastern Daylight Time. A live audio webcast of the meeting will be available on the Investor Relations section of the Company's corporate website at www.biogen.com/investors or directly via www.virtualshareholdermeeting.com/BIIB. An archive of the webcast will be available for replay following the meeting. Please allow at least 10 minutes prior to the event to visit the site and download the necessary software to listen to the webcast.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

EN
31/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biogen Inc.

 PRESS RELEASE

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 ...

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome – Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments, with no currently approved medicines that address the underlying cause of the disease – CAMBRIDGE, Mass. and BEDFORD, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: B...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch